ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 10 mg/vial - pasireotide

ישראל - עברית - Ministry of Health

medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 30 mg/vial - pasireotide

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine as pamoate monohydrate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - olanzapine as pamoate monohydrate 405 mg - olanzapine

ישראל - עברית - Ministry of Health

neopharm ltd - bazedoxifene as acetate 20 mg - coated tablets - bazedoxifene - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefit

ישראל - עברית - Ministry of Health

neopharm ltd - sirolimus 1.00 mg - coated tablets - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

"טבע מדיקל (שיווק) בע""מ" - רופא - משתלים לכלי דם המכילים חומר מן החי+ חבישה לסגירה

ישראל - עברית - Ministry of Health

טבע מדיקל (שיווק) בע"מ - מומחה - כירורגיית כלי דם: ראה הוראות שימוש

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine as pamoate monohydrate 405 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

lidorr chemicals ltd - febantel 1.5 g / 100 ml; pyrantel pamoate 1.44 g / 100 ml - suspension - for the treatment and control of roundworms (ascarids), in particular toxocara canis, of puppies and young dogs up to one year of age.